Developer docs
API playgroundTry for free, no card

Search company profiles

Fusion Clinical Research

Full company profile

uuid004gphp

Namestring
Fusion Clinical Research
Legal namestring
CMAX Clinical Research Pty Ltd
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Fusion Clinical Research is a South Australia-based contract research organisation (CRO) that operates Phase II-IV clinical trials on behalf of global pharmaceutical companies, biotechnology firms, and CROs. Founded in 2018 as the later-phase division of CMAX Clinical Research, one of Australia's oldest Phase I units, Fusion conducts its work from a purpose-built facility in Norwood, Adelaide, and supports trials across therapeutic areas including vaccination, weight management, cardiovascular disease, COPD, hypertension, and respiratory infections.

The company's core service is end-to-end late-phase trial execution: patient recruitment, protocol delivery, data management, quality assurance, and close-out activities, staffed by an in-house team of doctors, nurses, scientists, and technicians. Recruitment is underpinned by a database of more than 10,000 active participants and a referral network spanning GPs and specialists across multiple disciplines (cardiology, dermatology, neurology, endocrinology, ophthalmology, immunology, radiology, pain, bariatrics, and lipidology).

Fusion monetises through professional-services contracts with sponsors and CROs, leveraging Australia's Clinical Trials Notification (CTN) scheme (4-8 week review cycles) and the R&D Tax Incentive (up to 43.5% rebate) to improve economics. The business development function sells directly into enterprise pharma and global CRO accounts, with a public sponsor roster that includes Sanofi, Eli Lilly, AstraZeneca, GSK, AMGEN, IQVIA, ICON, PPD, and Novotech. Revenue is not disclosed; the legal entity is CMAX Clinical Research Pty Ltd.

Short descriptiontext

Fusion Clinical Research is a South Australian CRO that runs Phase II-IV clinical trials for global pharma, biotech, and CROs from its Norwood facility, recruiting via a 10,000+ participant database and a national GP/specialist referral network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNorwood, Australia
HQ citystring
Norwood
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial services, late phase trials, patient recruitment, vaccine clinical trials, clinical research operations
Industry2 codes
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAGACAF
Investigator & Site Training / GCP Support
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Trial Services
TypeProfessional Services
Description

Fusion Clinical Research generates revenue by conducting Phase II-IV clinical trials for pharmaceutical companies, biotech firms, and CROs. Services include trial design support, patient recruitment through their GP network and database, trial execution, data management, and quality assurance.

fusiontrials.com.au
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details15 tiers
1F03825 Weight Management Trial: $75 per clinic visit + $48 for fasting visits
ModelOtherBilling cadencePay-as-you-go
Notes

Participants receive compensation of $75 per clinic visit and an additional $48 if the visit requires fasting to cover the cost of a meal. Study involves approximately 19 visits over 70 weeks, or 36 visits over 190 weeks for pre-diabetics.

fusiontrials.com.au
2F03725 Weight Management Trial: $106 per in-clinic visit, $53 per telehealth visit, $51 per DEXA scan
ModelOtherBilling cadencePay-as-you-go
Notes

$106 per in-clinic visit (14 visits including Screening), $53 per virtual telehealth visit (7 visits), $51 per DEXA scan (2 visits). Additional $30 per fasted clinic visit to cover meals if receipt is submitted.

fusiontrials.com.au
3F04026 Strep Throat & Rheumatic Fever Trial: $3,450 total
ModelOtherBilling cadencePay-as-you-go
Notes

Participants who qualify, enroll and complete all assessments/activities will receive $3,450. Pro-rata amounts apply if all activities have not been completed. Study lasts about 9 months with 9 visits.

fusiontrials.com.au
4F04126 Oral Weight Management Trial: Travel expense reimbursement only
ModelOtherBilling cadencePay-as-you-go
Notes

Participants who qualify and enrol will receive all study medication, health assessments, and laboratory tests at no cost. They will also be reimbursed for reasonable travel expenses. 16 visits over approximately 50 weeks.

fusiontrials.com.au
5F03225 COPD Trial: Reimbursement available (amount not specified)
ModelOtherBilling cadencePay-as-you-go
Notes

Reimbursement for time and travel may be available. Details provided by the study team. Adults 40+ with COPD, 9 visits over approximately 32 weeks.

fusiontrials.com.au
6F03625 Cardiovascular Trial: $75 per site visit + $48 for fasting visits
ModelOtherBilling cadencePay-as-you-go
Notes

Participants are compensated for their time of $75 per site visit and $48 for meals in the event the visit requires fasting. Approximately 30 or more visits over approximately 275 weeks (about 5 years).

fusiontrials.com.au
7F02724 Cardiovascular Trial: $100 per visit
ModelOtherBilling cadencePay-as-you-go
Notes

$100 per visit. Visits occur every 12 weeks, with some annual tests and evaluations. Adults 50+ with cardiac risk factors or history of heart disease.

fusiontrials.com.au
8F01924 Pneumococcal Vaccine Trial: $975-$1,275 depending on cohort
ModelOtherBilling cadencePay-as-you-go
Notes

$975 for Cohort 1, $1,125 for Cohort 2, $1,275 for Cohort 3. 4 visits over 11 weeks and 3 phone calls. Adults 70 and over.

fusiontrials.com.au
9F01123 Lorundrostat Hypertension Trial: $60 per visit
ModelOtherBilling cadencePay-as-you-go
Notes

$60 for each visit including the screening visits. 9 clinical visits over 18 weeks. Adults 18+ with hypertension.

fusiontrials.com.au
10C02722 Hypertension Trial: $7,330 total
ModelOtherBilling cadencePay-as-you-go
Notes

$7,330 for completing the study. 2 nights overnight stay plus 13 follow-up visits. Adults 18-72 with mild hypertension.

fusiontrials.com.au
11C04723 COPD Trial: $6,320 total
ModelOtherBilling cadencePay-as-you-go
Notes

$6,320 for completing the study. 11 consecutive nights at Adelaide based CMAX facility plus 1 follow-up phone call. Adults 35-80.

fusiontrials.com.au
12F03525 Heart & Kidney Health Trial: $75 per visit
ModelOtherBilling cadencePay-as-you-go
Notes

$75 per visit reimbursement for time and travel. Minimum 15 visits over 3.5+ years. Adults 50+ with heart disease and/or chronic kidney disease.

fusiontrials.com.au
13F02925 Respiratory Viruses Trial: $2,200 total
ModelOtherBilling cadencePay-as-you-go
Notes

$2,200 for completing the study. 7 visits including screening plus 4 phone calls over 2 years. Adults 60-85.

fusiontrials.com.au
14F00723 Obesity & Cardiovascular Disease Trial: $60 per visit
ModelOtherBilling cadencePay-as-you-go
Notes

$60 per visit if pass screening and when enrolled on the study (not for screening visit). Study runs 113 weeks. Adults with obesity and cardiovascular disease.

fusiontrials.com.au
15F01023 Weight Management Trial: $120 per visit + $25 for fasting
ModelOtherBilling cadencePay-as-you-go
Notes

$120 per visit (fasting visits receive an additional $25 to cover meals). Approximately 42 weeks duration.

fusiontrials.com.au
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Fusion Clinical Research conducts Phase II-IV clinical trials for pharmaceutical companies, biotechnology firms, digital health companies, and Contract Research Organisations. Its two core service lines are Vaccination Clinical Trials and Medical Condition and Disease Clinical Trials, delivered end-to-end from start-up through close-out, including patient recruitment via an in-house database of 10,000+ participants and a GP/specialist referral network, trial management, data services, and quality assurance aligned with international GCP standards.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 4-8 week review cycle for clinical trial approvals under Australia's CTN scheme
Product overview1 text field

Fusion Clinical Research is South Australia's leading later phase clinical trial operator, launched in 2018 as a division of CMAX Clinical Research. The company operates two core service lines: Vaccination Clinical Trials (covering pneumococcal, norovirus, RSV, COVID-19, influenza, and combination vaccines) and Medical Condition and Disease Clinical Trials (spanning mental health, sleep disorders, cardiac, obesity/metabolic disorders, diabetes, and dermatology). The company conducts Phase II-IV clinical trials from its purpose-built facility in Norwood, Adelaide, offering end-to-end trial services including patient recruitment via a database of more than 10,000 participants, trial management, data services, and quality assurance. Fusion's network of General Practitioners and Specialists enables connection to patients for local and international pharmaceutical, biotech, digital health, and clinical research organisations.

Product and service6 records
1Vaccination Clinical Trials
CategoryVaccination Clinical Trials
Description

End-to-end Phase II-IV clinical trial services for vaccine sponsors, evaluating investigational vaccines including pneumococcal, norovirus, RSV, COVID-19, influenza, and combination vaccines (COVID-19/influenza). Targeted at pharmaceutical companies, biotech firms, and CROs seeking vaccine trial execution in Australia.

2Medical Condition and Disease Clinical Trials
CategoryMedical Condition and Disease Clinical Trials
Description

End-to-end Phase II-IV clinical trial services across therapeutic areas including mental health, sleep disorders, cardiac, obesity and metabolic disorders, diabetes, and dermatology. Targeted at pharmaceutical companies, biotech firms, digital health companies, and CROs requiring late-phase trial execution in Australia.

3Weight Management Trials
CategoryMedical Condition and Disease Clinical Trials
Description

Later phase clinical trials evaluating investigational weight management treatments including oral medications and subcutaneous injections in adults aged 18 or older who are overweight. Targeted at pharmaceutical and biotech sponsors developing obesity therapeutics.

4Cardiovascular Trials
CategoryMedical Condition and Disease Clinical Trials
Description

Clinical trials testing investigational cardiovascular medicines for adults with elevated Lipoprotein(a) levels or cardiovascular disease risk. Targeted at pharmaceutical and biotech sponsors developing cardiovascular therapeutics, including studies such as F03625.

5COPD Trial (F03225)
CategoryMedical Condition and Disease Clinical Trials
Description

Clinical research study testing an investigational medication for moderate to very severe chronic obstructive pulmonary disease (COPD) in adults 40+ with COPD, with 9 visits over approximately 32 weeks. Targeted at pharmaceutical sponsors developing respiratory therapeutics.

6Strep Throat & Rheumatic Fever Vaccine Trial (F04026)
CategoryVaccination Clinical Trials
Description

Clinical research study evaluating an investigational vaccine to prevent Streptococcal infections in adults aged 18-40, with 9 visits over approximately 9 months and total participant compensation of $3,450 upon completion. Targeted at pharmaceutical vaccine sponsors.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Fusion Clinical Research is a division of CMAX Clinical Research Pty Ltd. Fusion was launched in 2018 as the Phase II-IV Division to CMAX Clinical Research, expanding the service to later phase trials. CMAX is described as one of Australia's oldest and most successful Phase I clinical trials units. All privacy policies and corporate governance reference the parent company CMAX.

Strategic tierMinorTypeOthers
Description

Global pharmaceutical company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.

Strategic tierMinorTypeOthers
Description

Global CRO that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.

Strategic tierMinorTypeOthers
Description

APAC-focused CRO that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.

Strategic tierMinorTypeOthers
Description

Healthcare technology and analytics company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.

Strategic tierMinorTypeOthers
Description

Global CRO that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.

Strategic tierMinorTypeOthers
Description

Global pharmaceutical company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.

Strategic tierMinorTypeOthers
Description

Global pharmaceutical company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.

Strategic tierMinorTypeOthers
Description

Global pharmaceutical company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.

Strategic tierMinorTypeOthers
Description

Global biotechnology company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Perth-based Australian clinical trial site conducting Phase I-IV trials with an active participant database. Most directly comparable to Fusion as a same-country, similar-phase late-phase operator competing for global sponsor placements in Australia.

TypeBroad incumbent
Description

APAC-focused CRO headquartered in Australia with extensive Phase I-IV site management. Both a Fusion client and the most direct regional competitor for late-phase trials across Australia and the broader Asia-Pacific region.

TypeDirect peer
Description

Fusion's parent company and one of Australia's oldest Phase I clinical trials units, based in Adelaide. Operates the same single-site Adelaide infrastructure and shares governance, making it the closest corporate and operational peer.

TypeDirect peer
Description

Australian early-phase clinical trial operator with sites in Melbourne and Brisbane. Comparable as a domestic Phase I/II competitor targeting the same pool of global sponsors and CRO partnerships, though with earlier-phase focus than Fusion.

TypeBroad incumbent
Description

Global CRO acquired by Thermo Fisher Scientific, providing full-service clinical development across all phases. Fusion customer and broad incumbent competing for sponsor trial placements worldwide.

TypeDirect peer
Description

Brisbane-based early-phase clinical trials unit focused on Phase I and first-in-human studies. Comparable as an Australian dedicated clinical trial site, with overlap in sponsor and CRO relationships even though its phase mix differs from Fusion.

TypeBroad incumbent
Description

Global CRO and healthcare data/analytics company that is both a Fusion client and a broad incumbent operating its own global site network. Comparable as a counterparty in clinical trial outsourcing decisions and as a benchmark for global CRO capabilities.

TypeBroad incumbent
Description

Global CRO with a broad Phase I-IV site network. Listed Fusion customer and a broad incumbent competing for the same late-phase sponsor programs at global scale.

TypeBroad incumbent
Description

Global CRO offering full-service Phase I-IV clinical development and site services. Comparable as a broad incumbent competing for the same global late-phase trial mandates that Fusion accesses through sponsor and CRO partnerships.

10Bellberry Limited
TypeRegional player
Description

South Australia-based Human Research Ethics Committee supporting Australian clinical trials. Not a direct site competitor but an institutional enabler whose review timelines shape how Fusion and other Australian sites operate in the same regulatory pathway.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fusion Clinical Research

Clinical Research Servicesfusiontrials.com.au

Fusion Clinical Research is a South Australian CRO that runs Phase II-IV clinical trials for global pharma, biotech, and CROs from its Norwood facility, recruiting via a 10,000+ participant database and a national GP/specialist referral network.

What Fusion Clinical Research does

Fusion Clinical Research is a South Australia-based contract research organisation (CRO) that operates Phase II-IV clinical trials on behalf of global pharmaceutical companies, biotechnology firms, and CROs. Founded in 2018 as the later-phase division of CMAX Clinical Research, one of Australia's oldest Phase I units, Fusion conducts its work from a purpose-built facility in Norwood, Adelaide, and supports trials across therapeutic areas including vaccination, weight management, cardiovascular disease, COPD, hypertension, and respiratory infections.

The company's core service is end-to-end late-phase trial execution: patient recruitment, protocol delivery, data management, quality assurance, and close-out activities, staffed by an in-house team of doctors, nurses, scientists, and technicians. Recruitment is underpinned by a database of more than 10,000 active participants and a referral network spanning GPs and specialists across multiple disciplines (cardiology, dermatology, neurology, endocrinology, ophthalmology, immunology, radiology, pain, bariatrics, and lipidology).

Fusion monetises through professional-services contracts with sponsors and CROs, leveraging Australia's Clinical Trials Notification (CTN) scheme (4-8 week review cycles) and the R&D Tax Incentive (up to 43.5% rebate) to improve economics. The business development function sells directly into enterprise pharma and global CRO accounts, with a public sponsor roster that includes Sanofi, Eli Lilly, AstraZeneca, GSK, AMGEN, IQVIA, ICON, PPD, and Novotech. Revenue is not disclosed; the legal entity is CMAX Clinical Research Pty Ltd.

Fusion Clinical Research firmographics

Firmographics
Name
Fusion Clinical Research
Legal name
CMAX Clinical Research Pty Ltd
Website
https://fusiontrials.com.au
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Fusion Clinical Research is a South Australian CRO that runs Phase II-IV clinical trials for global pharma, biotech, and CROs from its Norwood facility, recruiting via a 10,000+ participant database and a national GP/specialist referral network.
Ownership category
akta.pro rank

Fusion Clinical Research industry classification

Industry
Product category
Clinical Research Services
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAGACAF
Investigator & Site Training / GCP Support

Keywords

  • Clinical trial services
  • Late phase trials
  • Patient recruitment
  • Vaccine clinical trials
  • Clinical research operations

Where Fusion Clinical Research is headquartered

Location

Headquarters

HQ city
Norwood
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Fusion Clinical Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Clinical Trial Services: Fusion Clinical Research generates revenue by conducting Phase II-IV clinical trials for pharmaceutical companies, biotech firms, and CROs. Services include trial design support, patient recruitment through their GP network and database, trial execution, data management, and quality assurance.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goF03825 Weight Management Trial: $75 per clinic visit + $48 for fasting visits
OtherPay-as-you-goF03725 Weight Management Trial: $106 per in-clinic visit, $53 per telehealth visit, $51 per DEXA scan
OtherPay-as-you-goF04026 Strep Throat & Rheumatic Fever Trial: $3,450 total
OtherPay-as-you-goF04126 Oral Weight Management Trial: Travel expense reimbursement only
OtherPay-as-you-goF03225 COPD Trial: Reimbursement available (amount not specified)
OtherPay-as-you-goF03625 Cardiovascular Trial: $75 per site visit + $48 for fasting visits
OtherPay-as-you-goF02724 Cardiovascular Trial: $100 per visit
OtherPay-as-you-goF01924 Pneumococcal Vaccine Trial: $975-$1,275 depending on cohort
OtherPay-as-you-goF01123 Lorundrostat Hypertension Trial: $60 per visit
OtherPay-as-you-goC02722 Hypertension Trial: $7,330 total
OtherPay-as-you-goC04723 COPD Trial: $6,320 total
OtherPay-as-you-goF03525 Heart & Kidney Health Trial: $75 per visit
OtherPay-as-you-goF02925 Respiratory Viruses Trial: $2,200 total
OtherPay-as-you-goF00723 Obesity & Cardiovascular Disease Trial: $60 per visit
OtherPay-as-you-goF01023 Weight Management Trial: $120 per visit + $25 for fasting

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Fusion Clinical Research product offering

Product offering

Core offering

Fusion Clinical Research conducts Phase II-IV clinical trials for pharmaceutical companies, biotechnology firms, digital health companies, and Contract Research Organisations. Its two core service lines are Vaccination Clinical Trials and Medical Condition and Disease Clinical Trials, delivered end-to-end from start-up through close-out, including patient recruitment via an in-house database of 10,000+ participants and a GP/specialist referral network, trial management, data services, and quality assurance aligned with international GCP standards.

Product overview

Fusion Clinical Research is South Australia's leading later phase clinical trial operator, launched in 2018 as a division of CMAX Clinical Research. The company operates two core service lines: Vaccination Clinical Trials (covering pneumococcal, norovirus, RSV, COVID-19, influenza, and combination vaccines) and Medical Condition and Disease Clinical Trials (spanning mental health, sleep disorders, cardiac, obesity/metabolic disorders, diabetes, and dermatology). The company conducts Phase II-IV clinical trials from its purpose-built facility in Norwood, Adelaide, offering end-to-end trial services including patient recruitment via a database of more than 10,000 participants, trial management, data services, and quality assurance. Fusion's network of General Practitioners and Specialists enables connection to patients for local and international pharmaceutical, biotech, digital health, and clinical research organisations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Vaccination Clinical Trials End-to-end Phase II-IV clinical trial services for vaccine sponsors, evaluating investigational vaccines including pneumococcal, norovirus, RSV, COVID-19, influenza, and combination vaccines (COVID-19/influenza). Targeted at pharmaceutical companies, biotech firms, and CROs seeking vaccine trial execution in Australia.
  • Medical Condition and Disease Clinical Trials End-to-end Phase II-IV clinical trial services across therapeutic areas including mental health, sleep disorders, cardiac, obesity and metabolic disorders, diabetes, and dermatology. Targeted at pharmaceutical companies, biotech firms, digital health companies, and CROs requiring late-phase trial execution in Australia.
  • Weight Management Trials Later phase clinical trials evaluating investigational weight management treatments including oral medications and subcutaneous injections in adults aged 18 or older who are overweight. Targeted at pharmaceutical and biotech sponsors developing obesity therapeutics.
  • Cardiovascular Trials Clinical trials testing investigational cardiovascular medicines for adults with elevated Lipoprotein(a) levels or cardiovascular disease risk. Targeted at pharmaceutical and biotech sponsors developing cardiovascular therapeutics, including studies such as F03625.
  • COPD Trial (F03225) Clinical research study testing an investigational medication for moderate to very severe chronic obstructive pulmonary disease (COPD) in adults 40+ with COPD, with 9 visits over approximately 32 weeks. Targeted at pharmaceutical sponsors developing respiratory therapeutics.
  • Strep Throat & Rheumatic Fever Vaccine Trial (F04026) Clinical research study evaluating an investigational vaccine to prevent Streptococcal infections in adults aged 18-40, with 9 visits over approximately 9 months and total participant compensation of $3,450 upon completion. Targeted at pharmaceutical vaccine sponsors.

Quantifiable outcome

  • 4-8 week review cycle for clinical trial approvals under Australia's CTN scheme

Companies that use Fusion Clinical Research

Customer profile

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Fusion Clinical Research technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Fusion Clinical Research partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • CMAX Clinical ResearchcoreStrategic or Co-development PartnerFusion Clinical Research is a division of CMAX Clinical Research Pty Ltd. Fusion was launched in 2018 as the Phase II-IV Division to CMAX Clinical Research, expanding the service to later phase trials. CMAX is described as one of Australia's oldest and most successful Phase I clinical trials units. All privacy policies and corporate governance reference the parent company CMAX.
  • SanofiminorOthersGlobal pharmaceutical company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
  • PPD (Pharmaceutical Product Development)minorOthersGlobal CRO that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
  • NovotechminorOthersAPAC-focused CRO that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
  • IQVIAminorOthersHealthcare technology and analytics company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
  • ICONminorOthersGlobal CRO that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
  • GSK (GlaxoSmithKline)minorOthersGlobal pharmaceutical company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
  • Eli LillyminorOthersGlobal pharmaceutical company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
  • AstraZenecaminorOthersGlobal pharmaceutical company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.
  • AMGENminorOthersGlobal biotechnology company that chooses Fusion Clinical Research as their clinical trial operator. Listed among global pharma and biotech leaders that partner with Fusion.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Fusion Clinical Research competitors and assessment

Company assessment

Direct peers

  • Linear Clinical Research: Perth-based Australian clinical trial site conducting Phase I-IV trials with an active participant database. Most directly comparable to Fusion as a same-country, similar-phase late-phase operator competing for global sponsor placements in Australia.
  • CMAX Clinical Research: Fusion's parent company and one of Australia's oldest Phase I clinical trials units, based in Adelaide. Operates the same single-site Adelaide infrastructure and shares governance, making it the closest corporate and operational peer.
  • Nucleus Network: Australian early-phase clinical trial operator with sites in Melbourne and Brisbane. Comparable as a domestic Phase I/II competitor targeting the same pool of global sponsors and CRO partnerships, though with earlier-phase focus than Fusion.
  • Q-Pharm: Brisbane-based early-phase clinical trials unit focused on Phase I and first-in-human studies. Comparable as an Australian dedicated clinical trial site, with overlap in sponsor and CRO relationships even though its phase mix differs from Fusion.

Broad incumbents

  • Novotech: APAC-focused CRO headquartered in Australia with extensive Phase I-IV site management. Both a Fusion client and the most direct regional competitor for late-phase trials across Australia and the broader Asia-Pacific region.
  • PPD (Thermo Fisher Scientific): Global CRO acquired by Thermo Fisher Scientific, providing full-service clinical development across all phases. Fusion customer and broad incumbent competing for sponsor trial placements worldwide.
  • IQVIA: Global CRO and healthcare data/analytics company that is both a Fusion client and a broad incumbent operating its own global site network. Comparable as a counterparty in clinical trial outsourcing decisions and as a benchmark for global CRO capabilities.
  • ICON plc: Global CRO with a broad Phase I-IV site network. Listed Fusion customer and a broad incumbent competing for the same late-phase sponsor programs at global scale.
  • Parexel International: Global CRO offering full-service Phase I-IV clinical development and site services. Comparable as a broad incumbent competing for the same global late-phase trial mandates that Fusion accesses through sponsor and CRO partnerships.

Regional players

  • Bellberry Limited: South Australia-based Human Research Ethics Committee supporting Australian clinical trials. Not a direct site competitor but an institutional enabler whose review timelines shape how Fusion and other Australian sites operate in the same regulatory pathway.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Fusion Clinical Research social profiles

Digital presence

Fusion Clinical Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fusion Clinical Research leadership team

Management profile

Number of profiles

Profiles10 records

Fusion Clinical Research funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fusion Clinical Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fusion Clinical Research

What does Fusion Clinical Research do?

Fusion Clinical Research conducts Phase II-IV clinical trials for pharmaceutical companies, biotechnology firms, digital health companies, and Contract Research Organisations. Its two core service lines are Vaccination Clinical Trials and Medical Condition and Disease Clinical Trials, delivered end-to-end from start-up through close-out, including patient recruitment via an in-house database of 10,000+ participants and a GP/specialist referral network, trial management, data services, and quality assurance aligned with international GCP standards.

Is Fusion Clinical Research a public or private company?

Fusion Clinical Research is a private company. It is classified as corporate owned and is currently operating.

When was Fusion Clinical Research founded?

Fusion Clinical Research was founded in 2018. It employs 11 to 50 people.

Where is Fusion Clinical Research based?

Fusion Clinical Research is headquartered in Norwood, Australia, in the Oceania region.

How does Fusion Clinical Research make money?

One revenue line is on record: clinical Trial Services.

Who are Fusion Clinical Research's main competitors?

Direct peers on record are Linear Clinical Research, CMAX Clinical Research, Nucleus Network and Q-Pharm. Broad incumbents are Novotech, PPD (Thermo Fisher Scientific), IQVIA, ICON plc and Parexel International. Bellberry Limited is listed as a regional player.

Does Fusion Clinical Research have an API?

No public API is recorded for Fusion Clinical Research.

What industry is Fusion Clinical Research in?

Fusion Clinical Research's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination, with a secondary code of HLAGACAF, Investigator & Site Training / GCP Support. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales